Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-11-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
上海信公轶禾企业管理咨询有限公司关于上海美迪西生物医药股份有限公司2020年限制性股票激励计划限制性股票授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2020 Restricted Stock Incentive Plan for Shanghai Medicilon Inc. It contains detailed information about the stock incentive plan, including the number of shares granted, grant price, conditions for granting and vesting, approval procedures, and the advisor's verification opinions. The document is not a general annual report or earnings release but a specialized advisory report on a capital incentive plan. It is not a mere announcement or proxy solicitation but a comprehensive independent financial advisor report. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives.
2020-11-13 Chinese
关于向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of restricted stock to incentive recipients by Shanghai Medicilon Inc. It includes specifics such as the grant date, number of shares, price, approval procedures, legal opinions, and financial impact of the stock incentive plan. The content focuses on the company's equity incentive plan and stock grants to directors, senior management, and key personnel. This type of document is a formal announcement about a share-based compensation plan, which falls under capital or financing activities related to share issuance and equity incentives. It is not a full financial report, audit report, or management discussion, nor is it a voting result or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the stock grant, not just a brief notice or report publication announcement.
2020-11-13 Chinese
关于公司2020年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2020 restricted stock incentive plan. It details the investigation of insider trading activities by persons aware of the insider information, confirming no violations were found. The document is an announcement about compliance and insider trading checks, not a financial report, earnings release, or management report. It does not contain financial statements or detailed financial data. It is a regulatory disclosure related to insider trading compliance and stock incentive plans, fitting best under Regulatory Filings (RNS). The document length is short (1290 characters), and it is a formal announcement rather than a report or presentation.
2020-11-13 Chinese
监事会关于公司2020年限制性股票激励计划激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board of Shanghai Medicilon Inc. regarding the verification and disclosure of the list of incentive recipients under the company's 2020 restricted stock incentive plan. It includes details about the legal compliance, public disclosure period, and verification process of the incentive recipients. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to a stock incentive plan and the supervisory board's verification opinion. This fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories like capital changes or remuneration reports.
2020-11-06 Chinese
2020年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2020 First Extraordinary General Meeting (EGM) Meeting Materials" of Shanghai Medicilon Inc. It contains detailed meeting instructions, agenda, and proposals to be discussed and voted on at the EGM, including stock incentive plans and authorizations for the board. The content is focused on the meeting materials provided to shareholders for the EGM, not the announcement of voting results or the minutes of the meeting. It is not a full annual report, earnings release, or other financial report. The document is a presentation of materials for a shareholders meeting, specifically an extraordinary general meeting, which fits the category of AGM Information (AGM-R) as it includes presentations and materials shared during the meeting. The document length (6865 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or notice. Therefore, the correct classification is AGM Information (AGM-R).
2020-11-05 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from a sponsoring securities company (广发证券股份有限公司) regarding the use of part of idle raised funds by Shanghai Medicilon Inc. for cash management. It references regulatory guidelines on the management and use of raised funds, details the amount, investment products, risk controls, and approvals by the board and supervisory committee. The document is not an announcement of a report publication but a substantive compliance and verification report related to the use of raised funds. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a capital raising update (CAP) but rather a regulatory compliance and verification report on the use of funds. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories like capital update or audit report. The document length is under 5,000 characters, but it is substantive and not merely an announcement. Therefore, the best classification is Regulatory Filings (RNS).
2020-10-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.